Walk in New York opens to aid access to advanced mobility devices
Wandercraft has launched Walk in New York, a new rehabilitation center that offers access to its advanced mobility…
Articles by Andrea Lobo, PhD
Multiple Sclerosis Association of America to host annual fundraiser
The Multiple Sclerosis Association of America (MSAA) will host its 11th annual Improving Lives Benefit on May 14…
Resistance training program didn’t cut cardiovascular risk in SPMS
While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis  (SPMS) in…
Yoga Moves MS forum on May 21 to address intimacy, sexuality
Intimacy and sexuality among people with multiple sclerosis (MS) will be the focus of this year’s Holistic Health and…
Medicaid coverage tied to worse MS outcomes for US patients: Study
Medicaid coverage for people with multiple sclerosis (MS) in the U.S. is associated with worse disease outcomes — including more…
AAN 2025: CAR T-cell therapy for MS shows safety, efficacy in trials
Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy,…
Foralumab Phase 2a trial starts dosing patients at Yale MS Center
A multicenter Phase 2a clinical trial testing Tiziana Life Sciences’ foralumab nasal spray in people with nonactive secondary progressive…
Ocrevus, fampridine improve walking ability in MS: Review
Fampridine, which is approved to improve walking in people with multiple sclerosis (MS), and the disease-modifying therapy Ocrevus…
FDA approves prefilled syringe formulation of Ani’s Cortrophin Gel
The U.S. Food and Drug Administration (FDA) has approved a prefilled syringe format for Ani Pharmaceuticals’ purified Cortrophin Gel…
PIRA linked to worse quality of life in early RRMS patients
Disability progression independent of relapse activity, or PIRA, in the earliest stages of relapsing-remitting multiple sclerosis (RRMS) is associated…
ACTRIMS 2025: Tolebrutinib impact greater in MS patients with PRLs
Note: This story was updated March 6, 2025, to clarify the specific disability measures and results assessed in each…
ACTRIMS 2025: Combining risk scores may accurately predict MS
A new model that combines genetic and symptom-based risk scores to predict the development of multiple sclerosis (MS) could…
Tiziana, Renaissance partner to accelerate intranasal foralumab
Tiziana Life Sciences is partnering with a contract development and manufacturing organization with expertise in intranasal drugs to accelerate the…
Expanded access program doses 4 new patients with nasal foralumab
Four more people with nonactive secondary progressive multiple sclerosis (SPMS) have received foralumab nasal spray — Tiziana Life…
First-line Ocrevus may aid early relapsing MS long-term outcomes
Using Ocrevus (ocrelizumab) as a first-line treatment for early-stage relapsing forms of multiple sclerosis (MS) is significantly better…
Switching from CD20 inhibitors to fumarates may be OK in stable MS
Switching from anti-CD20 medications to less effective fumarate therapies is linked to reduced healthcare visits and costs related to infections…
Enigma to use Neuraly’s PET tracer to monitor MS neuroinflammation
Enigma Biomedical has entered into an agreement with Neuraly to use its PET imaging tracer PMI04 to visualize…
Enrollment complete in Phase 2 trial of remyelination therapy for RRMS
Patient enrollment has been completed ahead of schedule in a Phase 2 clinical trial evaluating Contineum Therapeutics‘ PIPE-307, an…
Immutep MS therapy IMP761 found safe in initial Phase 1 trial data
IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a…
Therapy for immune tolerance in MS shows safety in early trial
LPX-TI641, Lapix Therapeutics‘ experimental oral therapy to restore immune system balance in people with multiple sclerosis (MS)…
AI tool aims to accelerate clinical trial patient recruitment
An artificial intelligence (AI)-based tool called Muse aims to accelerate drug development by optimizing clinical trial patient recruitment. The tool,…
New Cionic partnership will expand veterans’ access to Neural Sleeve
Cionic has partnered with Lovell Government Services, a veteran-owned business, to expand veterans’ access to its Neural Sleeve,…
MS Society of Canada starts annual Read-a-Thon fundraiser Oct. 14
The MS Society of Canada is hosting its annual MS Read-a-Thon, a fundraiser where children are encouraged to…
MS cell-based therapy PTG-007 wins patent protection in China
Poltreg will receive a patent in China that covers the administration of its cell-based therapy PTG-007 for multiple sclerosis…
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of…
Neufit’s MS Bootcamp offers intensive 3-day rehab experience
Neufit is encouraging people with multiple sclerosis (MS) to register for its upcoming MS Bootcamp, a three-day event…
Rituximab treatment stabilizes disability in SPMS patients: Analysis
Treatment with rituximab, a CD20 inhibitor used off-label for multiple sclerosis (MS) patients, can stabilize disability progression and reduce…
Tolebrutinib delays disability progression in nonrelapsing SPMS
Treatment with the investigational BTK inhibitor tolebrutinib significantly delayed the onset of confirmed disability progression in people with nonrelapsing…
Iaso Bio’s experimental CAR T-cell therapy cleared for testing in MS
Iaso Biotherapeutics has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials…
National MS Society names Coetzee president and CEO
The National Multiple Sclerosis Society (NMSS) said it named Tim Coetzee, PhD, president and chief executive officer. Coetzee had…